Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Therapy of erectile dysfunction in 2005].

H Porst1

  • 1Hamburg. Porst20354@aol.com

Der Urologe. Ausg. A
|October 22, 2003
PubMed
Summary

Future erectile dysfunction (ED) treatments will focus on the L-arginine-NO-guanylate cyclase-cGMP-PDE-5 pathway, with new drugs offering longer efficacy windows or daily low-dose applications for improved outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value of prolonged scrotal drainage after penile prosthesis implantation: a multicenter prospective nonrandomized pilot study.

International journal of impotence research·2023
Same author

Physicians' attitudes towards androgen replacement therapy for male and female sexual dysfunction.

International journal of impotence research·2016
Same author

Results from an online survey investigating ED patients' insights and treatment expectations.

International journal of impotence research·2015
Same author

Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study.

International journal of clinical practice·2014
Same author

Genetic association study of the GNB3 C825T, the ACE I/D and the eNOS G894T polymorphisms and the risk to develop erectile dysfunction in a German ED population.

Andrologia·2010
Same author

[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].

Der Urologe. Ausg. A·2009

Area of Science:

  • Urology
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Current erectile dysfunction (ED) management relies heavily on the L-arginine-NO-guanylate cyclase-cGMP-PDE-5 pathway.
  • The pathway's intracellular cGMP concentrations are key targets for ED therapies.

Purpose of the Study:

  • To explore emerging therapeutic strategies for ED beyond traditional PDE-5 inhibitors.
  • To investigate novel drug candidates and administration methods for improved ED management.
  • To highlight potential benefits of ED treatments for cardiovascular diseases and lower urinary tract symptoms (LUTS).

Main Methods:

  • Review of current and future therapeutic targets within the L-arginine-NO-guanylate cyclase-cGMP-PDE-5 pathway.
  • Evaluation of alternative drug classes, including guanylate cyclase activators and Rho-kinase inhibitors.
  • Assessment of novel administration routes like intranasal PT 141 (Melanotan II).

Main Results:

  • The L-arginine-NO-guanylate cyclase-cGMP-PDE-5 pathway will remain central to ED treatment in the next 3-5 years.
  • Guanylate cyclase activators and Rho-kinase inhibitors show promise as adjuncts or alternatives to PDE-5 inhibitors.
  • Intranasal PT 141 (Melanotan II) presents a promising novel therapeutic option.
  • Future ED therapies may involve longer efficacy windows (1-2 days) or daily low-dose bedtime applications for nocturnal reoxygenation and functional improvement.
  • Elevating cGMP levels and improving endothelial function offer potential benefits for cardiovascular health and LUTS.

Conclusions:

  • The future of ED management involves diversifying therapeutic targets and administration methods.
  • Novel approaches promise improved efficacy, patient convenience, and broader health benefits.
  • Integrated treatment strategies may address ED, cardiovascular issues, and LUTS concurrently.

Related Experiment Videos